SHENZHEN, CHINA – July 17, 2025 – Optoseeker Biotech, an innovator in advanced life science instrumentation, and BioMap, a pioneer in life science AI, today announced a strategic collaboration set to dramatically accelerate the development of novel antibody therapeutics.
This powerful partnership integrates Optoseeker Biotech's proprietary high-throughput cell screening instrument, the OptoBot® platform, with BioMap's domain-specific life science agent development capabilities. The collaboration aims to overcome critical bottlenecks in drug discovery by creating a seamless workflow that can identify promising antibody candidates with unprecedented speed and precision.
"We are thrilled to partner with BioMap, a pioneer in AI for life sciences," said Dr. Hainan Xie the CEO of Optoseeker Biotech. "Our OptoBot® platform is designed to generate functional single-cell data at a scale and depth previously unattainable. By combining our technology with BioMap's powerful analytical capabilities, we are not just accelerating a process; we are creating a new paradigm for discovering therapeutics. This is a validation of our technology's immense potential."
"The future of drug discovery lies in the convergence of high-quality biological data and advanced artificial intelligence," commented Dr. Ziyao Xu the Director of Strategy Department of BioMap. " Optoseeker Biotech’s high-throughput screening technology provides the scale and resolution our AI models require. This collaboration will unlock new biological insights and help move the biopharmaceutical industry toward a more automated, intelligent era."
This partnership underscores Optoseeker Biotech’s and BioMap's robust innovation engines, strong growth trajectory, and the significant market opportunities embodied in their co-developed platform technology.
About Optoseeker Biotech:
Optoseeker Biotech is dedicated to developing cutting-edge life science instruments to accelerate biological research and development. The company has successfully built the OptoBot® series of products with its own independent intellectual property rights, deeply integrating core technologies such as optoelectronic tweezers (OET), microfluidics, biochips, fluorescent staining, and protein labeling.
Its core advantage lies in the ability to achieve full-process automation from single-cell importation, culture, characterization, and sorting to exportation, significantly improving experimental efficiency and reproducibility. It provides researchers with powerful tools for high-throughput single-cell analysis and manipulation, continuously driving innovation in the biomedical field.
Currently, our core products include optofluidic systems, digital microfluidic systems, structured light projectors, and more. Our applications cover multiple fields, including antibody drug development, cell line development, cell and gene therapy (CGT), and micro-nano manipulation, providing a solid guarantee for our customers' research and production activities.
About BioMap:
BioMap is a global pioneer in foundational models for life sciences. Our 210-billion-parameter biological language model decodes the fundamental principles of genomes, proteins, cells, and biological systems. Functioning as a high-fidelity biological simulator, it significantly reduces reliance on traditional experimental models, accelerating and empowering R&D.
To date, BioMap has achieved state-of-the-art (SOTA) results across 200+ tasks spanning drug discovery, biomanufacturing, fundamental research, and healthcare. We deliver model-driven professional AI agents to 700+ global clients in dozens of specialized domains. By integrating data, modeling, and experimental capabilities, we enable cutting-edge outcomes including accelerated drug discovery, boosted bio-reaction efficiency, advanced biological data interpretation, and streamlined knowledge acquisition.
